Open Access

Effect of postoperative systemic antipsychotic therapy on psychiatric recurrence in patients with meningiomas

  • Authors:
    • Ping Yang
    • Liang Li
    • Mao‑Sheng Li
    • Bin Zhou
    • Wei‑Ping Kuang
    • Hui‑Yong Huang
  • View Affiliations

  • Published online on: May 21, 2018     https://doi.org/10.3892/ol.2018.8753
  • Pages: 956-962
  • Copyright: © Yang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

A number of patients with meningiomas and psychiatric disorders will suffer psychiatric symptom recurrence following tumorectomies. The present study reported a retrospective analysis regarding 42 cases of patients with meningiomas using complete clinical follow‑up data from June 2005 to June 2013. The patients were divided into the systemic antipsychotic (SP) group (n=20) following 6months of postoperative SP therapy and the none‑SP (NSP) group (n=22), who did not receive postoperative antipsychotic treatment. Patients were assessed using the Positive and Negative Syndrome Scale (PANSS) and Brief Psychiatric Rating Scale (BPRS) at the time points of prior to surgery, immediately following surgery, and 6 months, 12 months and 3 years following surgery. The effective rate, recurrence rate, rehospitalization rate and survival analysis were calculated. The BPRS score and PANSS scores (including PANSS positive, PANSS negative, PANSS general psychopathology and PANSS overall) in the SP group at 6 months, 12 months and 3 years following surgery were significantly decreased compared with the NSP group (P<0.05). The effective rate was 95, 90 and 90% at 6 months, 12 months and 3 years, respectively, in the SP group, whilst it was 68.2, 63.6 and 59%, respectively, in the NSP group, which was statistically significant (χ2=4.89, χ2=4.01 and χ2=5.12; P<0.05). The recurrence rate of the SP group was 0, 5 and 10% at 6 months, 12 months and 3 years, respectively, whilst in the NSP group it was 22.7, 31.8 and 54.5%, respectively, which was statistically significant (χ2=5.16, χ2=4.89 and χ2=9.34; P<0.05). The rehospitalization rate of the SP group was 0, 0 and 5% at 6 months, 12 months and 3 years, respectively, whilst in the NSP group it was 13.6, 22.7 and 36.4%, respectively, and the data at 12 months and 3 years was statistically significant (χ2=5.16 and χ2=6.12; P<0.05). Kaplan‑Meier survival analysis indicated that the accumulative survival rates of recurrence and rehospitalization in the SP group were improved compared with the NSP group. The log‑rank of recurrence was χ2=9.369 (P=0.002) and the log‑rank of rehospitalization was χ2=6.330 (P=0.012). In conclusion, postoperative SP therapy is of great importance to the consolidation of mental symptoms in patients with meningiomas and psychiatric symptoms, and it may significantly reduce the recurrence and rehospitalization rates.
View Figures
View References

Related Articles

Journal Cover

July-2018
Volume 16 Issue 1

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Yang P, Li L, Li MS, Zhou B, Kuang WP and Huang HY: Effect of postoperative systemic antipsychotic therapy on psychiatric recurrence in patients with meningiomas. Oncol Lett 16: 956-962, 2018
APA
Yang, P., Li, L., Li, M., Zhou, B., Kuang, W., & Huang, H. (2018). Effect of postoperative systemic antipsychotic therapy on psychiatric recurrence in patients with meningiomas. Oncology Letters, 16, 956-962. https://doi.org/10.3892/ol.2018.8753
MLA
Yang, P., Li, L., Li, M., Zhou, B., Kuang, W., Huang, H."Effect of postoperative systemic antipsychotic therapy on psychiatric recurrence in patients with meningiomas". Oncology Letters 16.1 (2018): 956-962.
Chicago
Yang, P., Li, L., Li, M., Zhou, B., Kuang, W., Huang, H."Effect of postoperative systemic antipsychotic therapy on psychiatric recurrence in patients with meningiomas". Oncology Letters 16, no. 1 (2018): 956-962. https://doi.org/10.3892/ol.2018.8753